INS and diabetes mellitus: On 21 March 2024, the Committee for Medicinal Products for Human Use (CHMP) of EMA adopted a positive opinion, recommending the granting of a marketing authorization for insulin Icodec, intended for the treatment of diabetes mellitus [166].